How effective is the antirheumatic drug baricitinib?

As an anti-rheumatic drug, the effect of baricitinib has been verified and affirmed in many aspects. Baricitinib is a new drug jointly developed by Incyte and the American pharmaceutical giant Eli Lilly. It can effectively inhibit JAK1, JAK2, and TYK2. These kinases play key roles in the pathogenesis of various inflammatory and autoimmune diseases, and therefore, baricitinib is expected to be widely used in the treatment of various inflammatory diseases.

In the clinical trial of RA-BEACON, researchers included 527 patients who had no response or low response to TNF inhibitors. After receiving baricitinib treatment, these patients' ACR20 scores improved significantly. What is more worth mentioning is that some patients showed improvement in ACR20 in the first week of treatment, demonstrating the rapid and significant efficacy of baricitinib.

Baricitinib is not only used to treat ankylosing spondylitis and rheumatoid arthritis, but also has certain improvement effects on psoriatic arthritis. This shows its potential in the treatment of a variety of rheumatic diseases.

Since2017, baricitinib has been approved for marketing in many countries and regions around the world, including the European Union, the United States, Japan, etc. These approvals were based on a rigorous evaluation of its efficacy and safety, further demonstrating the efficacy and reliability of baricitinib.

Although baricitinib is excellent in anti-rheumatic treatment, patients need to be aware of its possible side effects when using it. Common minor side effects include upper respiratory tract infection, nausea, etc., while serious side effects may include gastrointestinal perforation, high cholesterol, etc. Therefore, patients need to use it under the guidance of a doctor and undergo regular physical examinations.